Seagen to highlight data from novel targeted therapies at aacr

Bothell, wash.--(business wire)--seagen inc. (nasdaq: sgen) today announced that preclinical data from its pipeline of novel targeted oncology drugs will be presented at the american association for cancer research (aacr) annual meeting being held april 10-15, 2021. the oral and poster presentations will highlight several early-stage programs utilizing seagen's leading antibody-drug conjugate (adc) technology as well as its proprietary sugar-engineered antibody (sea) technology. “our research b
SGEN Ratings Summary
SGEN Quant Ranking